SAB Biotherapeutics (NASDAQ:SABS) Shares Down 1.4% - Here's What Happened

Key Points

• SAB Biotherapeutics shares fell about 1.4% mid-day to $3.48 (intraday low $3.41) on roughly 321,959 shares traded, a ~39% drop from average daily volume.
• Analyst views are mixed but skew positive with a MarketBeat consensus of Moderate Buy and an average target of $10.50; recent price targets range from $7 to $14 and ratings include 1 Strong Buy, 5 Buy and 2 Sell.
• The clinical-stage biotech (market cap ~$177.3M) develops human polyclonal antibodies via its Tc Bovine platform and recently missed quarterly EPS expectations (reported ($0.46) vs. consensus ($0.16)), with analysts forecasting about -0.72 EPS for the year.

SAB Biotherapeutics, Inc. (NASDAQ:SABS - Get Free Report)'s stock price was down 1.4% during mid-day trading on Wednesday . The company traded as low as $3.41 and last traded at $3.48. Approximately 321,959 shares were traded during mid-day trading, a decline of 39% from the average daily volume of 529,500 shares. The stock had previously closed at $3.53.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Wall Street Zen lowered SAB Biotherapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, March 14th. HC Wainwright decreased their price objective on SAB Biotherapeutics from $9.00 to $7.00 and set a "buy" rating for the company in a research report on Tuesday, March 10th. Weiss Ratings reissued a "sell (d+)" rating on shares of SAB Biotherapeutics in a research note on Friday, April 10th. Rodman & Renshaw started coverage on shares of SAB Biotherapeutics in a report on Thursday, April 2nd. They set a "buy" rating and a $13.00 target price on the stock. Finally, Chardan Capital lifted their price target on shares of SAB Biotherapeutics from $12.00 to $14.00 and gave the company a "buy" rating in a research note on Wednesday, March 11th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $10.50.

SAB Biotherapeutics Stock Performance

The company has a market capitalization of $177.31 million, a price-to-earnings ratio of -1.50 and a beta of 0.60. The stock's 50 day moving average price is $3.87 and its 200 day moving average price is $3.74. The company has a current ratio of 9.46, a quick ratio of 9.46 and a debt-to-equity ratio of 0.02.

SAB Biotherapeutics (NASDAQ:SABS - Get Free Report) last posted its quarterly earnings results on Monday, March 9th. The company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.30). Analysts expect that SAB Biotherapeutics, Inc. will post -0.72 earnings per share for the current year.

Institutional Trading of SAB Biotherapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. State of Wyoming acquired a new stake in shares of SAB Biotherapeutics in the fourth quarter valued at approximately $34,000. State Street Corp acquired a new position in shares of SAB Biotherapeutics during the 4th quarter worth approximately $49,000. ADAR1 Capital Management LLC bought a new stake in SAB Biotherapeutics in the 3rd quarter valued at $30,000. Fifth Lane Capital LP bought a new stake in SAB Biotherapeutics in the 4th quarter valued at $56,000. Finally, Dimensional Fund Advisors LP acquired a new stake in SAB Biotherapeutics during the 3rd quarter valued at $32,000. 7.82% of the stock is owned by institutional investors.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company's proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company's lead programs are directed primarily at infectious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.